DOCSLIB.ORG

Microsoft Outlook

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Microsoft Outlook Morris, Max From: Morris, Max Sent: Friday, April 30, 2021 7:34 PM To: Morris, Max Subject: 04/30/2021 Coronavirus Daily Recap This email is provided for informational, non-commercial purposes only. Use or reliance on the information contained in this email is at your sole risk. This email is not provided by or affiliated in any way with Ally Financial Inc. These updates are being shared to multiple organizations, individuals and lists who/which are bcc’d. Best effort we are sending Daily updates during the business week, typically in the evening, a Weekend Recap on Monday mornings, and any significant breaking news events provided anytime. Please note some numbers included in the Statistics and news stories come from various sources and so can vary as they are constantly changing and not reported at the same time. All communications are TLP GREEN and can be shared freely. Know someone who might want to be added to our Updates? Of course ask them first, and then have them send us an email to [email protected]. Live the message, share the message: Be safe – Stay home and limit travel as much as possible, self-quarantine if you or any members of your family are or may be sick, if you go out wear your mask – the right way, ensure safe social distancing, and practice good hygiene – wash your hands, avoid touching your face, and sanitize used items and surfaces. And be sure to get fully vaccinated to not only protect yourself but others. Need to find a vaccine? Here are a few good sites and resources we have come across that may help: CDC Vaccine Finder – https://vaccinefinder.org/ [Free government website where users can search for pharmacies and providers that offer vaccinations, currently limited number of states but expanding] Dr. B Standby list for COVID vaccines - https://hidrb.com/ [Sign-up website that connects eligible adults with leftover vaccines at risk of expiring] NBC News Plan Your Vaccine – https://www.nbcnews.com/specials/plan-your-vaccine/ [Website that walks you through eligibility, a timeline for when you can get vaccinated and where you can get a vaccine] Apple Maps App [Use the app to find vaccination location data from the US CDC's Vaccine Finder by searching or asking Siri, “Where can I get a Covid-19 vaccination?] Facebook Locator Tool [Access the social media’s Covid Information Center to see when and where to get vaccinated and get a link to make an appointment] Friday. Friday. Friday. So good we need to say it three times. Or even better shout it. A very good evening Everyone! We’re there. We’re done. Another week in the books. And once again you made it. Big exhale and what awaits us is rest, recharge and relaxation. But before we start, following is our Daily Recap of major Headlines, the “Good Stuff”, US Snapshots, US Vaccinations, US Variant Cases, key Highlights, as well as key Statistics, Vaccine and Treatment information, US Restrictions and the Back to Normal Index related to the novel coronavirus pandemic. Tonight, let’s consider the inspirational words from Aimee DuFresne, who said: Sometimes life hits the dimmer switch, and we think the light has gone out. But it is on. We have the ability to make it shine brightly and last forever. Keep Going. I’m sure we all can relate to thinking about our dimmer switches go down over and over during the last year. Many days that darkness overcame and overwhelmed us. Days when our hope seemed to fade and the promise of a brighter tomorrow was the farthest thing from our mind. But we found a way to get up the next day, push that switch up again and keep moving forward. Sometimes it was just a little push. Just a baby step. But doing our best to keep going, to find a way to keep at least a little light ahead in our focus. And as we have continued along our journey, the light has begun to get brighter and brighter. Just like that dimmer switch, we have kept pushing up and watching the darkness begin to recede. It was and is in us. To keep going. And keep moving. So, let’s keep that dimmer switch heading in the right direction. So be bright. Be a light. And go shine this weekend . 1 CVOB Website individual US State, US County, Global Trending Charts and Data as well as US Vaccinations, US Restrictions and our Communications Archive can be found at https://www.sunknighty.net/. Headlines There are now over 150 million cases of COVID-19 worldwide, according to a tally by Johns Hopkins University, a sobering number that comes less than 13 months after the World Health Organization officially declared the novel coronavirus outbreak had developed into a pandemic, with more than 905,000 new infections recorded globally on Wednesday alone. The wave of US coronavirus cases that began in early spring is on the wane, with the daily average of new infections around the country falling to their lowest level since mid-October, but the trend is not equal nationwide, with pockets of the country, including the Pacific Northwest, seeing a surge in outbreaks due to the emergency of new variant strains of the virus. For the first time, US patients between the ages of 18 and 64 now account for the largest cohort of the 37,000 total currently hospitalized with the virus, and with more older Americans vaccinated, this marks the third week that the number of hospitalized individuals in the 65 and older age group has been smaller than both the 18-49, and the 50- 64 age groups. A July 1 Covid-19 reopening plan - like one set out by New York City Mayor Bill de Blasio on Thursday, which targets reopening “100%” by then - is a “reasonable target” given falling cases and rising vaccination rates, Dr. Rochelle Walensky, the US Centers for Disease Control and Prevention director, said Friday, but cautioning about making specific predictions about what reopening could look like, saying “the virus has tricked us before.” One hundred million adults in the US are now fully vaccinated, Jeff Zients, who coordinates the White House coronavirus response team, said Friday. A figure that represents just under one-third of the total population. A single dose of Pfizer's coronavirus vaccine may not generate a sufficient immune response to protect against dominant new variants, except in people who have already been infected with COVID-19, according to a United Kingdom Imperial College-led study published on Friday, finding that those who had previously had mild or asymptomatic infection had enhanced protection against more infectious mutations that emerged in Britain and South Africa. It was anxiety - and not a problem with the shots - that caused fainting, dizziness and other short-term reactions in dozens of people at coronavirus vaccine clinics in five states, US health officials have concluded. People will likely need a booster about 9 to 12 months after their second dose of the Moderna Covid-19 vaccine, company president Stephen Hoge said Thursday, and hope that the boosters will not be necessary once the coronavirus pandemic is over. Data on how well the Pfizer-BioNTech Covid-19 vaccine works in kids ages 5 to 11 could be available as early as the end of this summer, and if clinical trials go well and the Food and Drug Administration approves it young children could get vaccinated by the end of the year, BioNTech o-founder and chief medical officer Dr. Ozlem Tureci said late Thursday. The Biden administration announced today it will restrict travel from India starting Tuesday, and is expected to issue a 212(f) order restricting entry into the US for foreign nationals who have been in the country within the previous 14 days, a policy won't apply to American citizens, lawful permanent residents or other people with exemptions. The Transportation Security Administration is extending the Biden-era transportation mask mandate, with the rule requiring face coverings on all travelers in airports, airplanes, terminals, trains, buses and boats, set to expire May 11, now lasting until September 13. India reported a new record rise in daily Covid-19 cases on Friday, in the middle of a deadly second wave that has crippled its health-care system and overwhelmed crematoriums, with health ministry data showing there were 386,452 infections over a 24-hour period — the highest daily increase globally, and Dr. Farah Husain, head of the Covid-19 ICU unit at Lok Nayak Hospital in Delhi, said the devastating outbreak in the country is “nothing short of an apocalypse.” China health officials say they are going on high alert after tracking fresh cases linked to a new mutation first discovered in India, with the country’s Center for Disease Control saying cities were picking up cases of the variant known as B.1.617 as it called for more stringent sanitation measures this weekend, when tens of millions of residents are expected to travel for the Labor Day holiday. 2 Liverpool on Wednesday hosted Britain’s first business conference since March 2020 and the northwestern English city will on Friday kick off a two-day nightclub event, the first in Britain in more than a year, and an outdoor music festival will take place on Sunday, all events that are part of a government research project to see how mass gatherings can happen safely. The key 10-year US Treasury yield edged lower on Friday following consumer spending data that showed significant jumps in personal income and spending as well as a rise in prices.
Load more

Recommended publications
  • Download PDF (2.6
    A Proposal to End the COVID-19 Pandemic Prepared by Ruchir Agarwal and Gita Gopinath* Authorized for distribution by Gita Gopinath DISCLAIMER: Staff Discussion Notes (SDNs) showcase policy-related analysis and research being developed by IMF staff members and are published to elicit comments and to encourage debate. The views expressed in Staff Discussion Notes are those of the author(s) and do not necessarily represent the views of the IMF, its Executive Board, or IMF management. Urgent steps are needed to arrest the rising human toll and economic strain from the COVID-19 pandemic that are exacerbating already-diverging recoveries. Pandemic policy is also economic policy as there is no durable end to the economic crisis without an end to the health crisis. Building on existing initiatives, this paper proposes pragmatic actions at the national and multilateral level to expeditiously defeat the pandemic. The proposal targets: (1) vaccinating at least 40 percent of the population in all countries by the end of 2021 and at least 60 percent by the first half of 2022, (2) tracking and insuring against downside risks, and (3) ensuring widespread testing and tracing, maintaining adequate stocks of therapeutics, and enforcing public health measures in places where vaccine coverage is low. The benefits of such measures at about $9 trillion far outweigh the costs which are estimated to be around $50 billion—of which $35 billion should be paid by grants from donors and the residual by national governments potentially with the support of concessional financing from bilateral and multilateral agencies. The grant funding gap identified by the Access to COVID-19 Tools (ACT) Accelerator amounts to about $22 billion, which the G20 recognizes as important to address.
    [Show full text]
  • Page 1 May 2021 SD N /2021/4
    May 2021 I M F S T A F F D I S C U S S I O N N O T E A Proposal to End the COVID-19 Pandemic SDN/2021/4 Ruchir Agarwal, Gita Gopinath DISCLAIMER: Staff Discussion Notes (SDNs) showcase policy-related analysis and research being developed by IMF staff members and are published to elicit comments and to encourage debate. The views expressed in Staff Discussion Notes are those of the author(s) and do not necessarily represent the views of the IMF, its Executive Board, or IMF management. A Proposal to End the COVID-19 Pandemic Prepared by Ruchir Agarwal and Gita Gopinath* Authorized for distribution by Gita Gopinath DISCLAIMER: Staff Discussion Notes (SDNs) showcase policy-related analysis and research being developed by IMF staff members and are published to elicit comments and to encourage debate. The views expressed in Staff Discussion Notes are those of the author(s) and do not necessarily represent the views of the IMF, its Executive Board, or IMF management. Urgent steps are needed to arrest the rising human toll and economic strain from the COVID-19 pandemic that are exacerbating already-diverging recoveries. Pandemic policy is also economic policy as there is no durable end to the economic crisis without an end to the health crisis. Building on existing initiatives, this paper proposes pragmatic actions at the national and multilateral level to expeditiously defeat the pandemic. The proposal targets: (1) vaccinating at least 40 percent of the population in all countries by the end of 2021 and at least 60 percent by the first half of 2022, (2) tracking and insuring against downside risks, and (3) ensuring widespread testing and tracing, maintaining adequate stocks of therapeutics, and enforcing public health measures in places where vaccine coverage is low.
    [Show full text]
  • Tuberculosis Diagnostic Research: Beyond the Basics December 13 - 15, 2010, Tuberculosis Research Centre, Chennai, India
    Tuberculosis Diagnostic Research: Beyond the Basics December 13 - 15, 2010, Tuberculosis Research Centre, Chennai, India COURSE SCHEDULE Monday, Dec 13, 2010 Time Lecture Faculty 8.30 AM Welcome and Introductions A Thomas, MS Jawahar, all 9.00 AM The global value chain (blueprint) for TB diagnostics and current M Pai pipeline of diagnostics 9.45 AM New WHO policy on Xpert MTB/RIF CN Paramasivan New WHO policy on serological assays K Steingart 10.30 AM Coffee 10.45 AM Overview of diagnostic research and types of diagnostic study M Pai designs 11.15 AM Landscape of TB diagnostic research M Pai 12.30 PM Lunch 1.30 PM The diagnostic test accuracy design M Pai 2.30 PM Bias in diagnostic research and sources of variation K Steingart 3.30 PM Coffee 4.00 - 5.30 PM Optimism bias in TB diagnostic research & critical appraisal M Pai Tuesday, Dec 14, 2010 Time Lecture Faculty 8.30 AM Setting reference standards in TB diagnostic studies: • Microscopy evaluations CN Paramasivan • Rapid culture methods CN Paramasivan • Molecular assays T Shinnick • Serological assays S Laal • IGRAs and LTBI tests M Pai • Extrapulmonary TB J Peter 10.30 AM Coffee 10.45 PM Lab accreditation and QA in India J Kenneth Ensuring quality in diagnostic trials: • Microscopy studies CN Paramasivan CN Paramasivan • Culture studies T Shinnick • Molecular assay studies S Laal • Immunodiagnostic studies 1 12.00 Noon Introduction to TB biomarker validation S Parida 12.30 PM Lunch 1.30 PM Beyond test accuracy - 1: impact of testing on diagnostic M Pai thinking and clinical decision
    [Show full text]
  • TB Diagnostics in India
    Content and themes This conference will convene industry leaders, innovative thinkers, A 2 researchers, funders, and policy makers, to stimulate increased - industry/biotech engagement in diagnostic innovations that can help TB conferenceday stimulate TB to diagnostics industry/biotech engagementinnovations in in India control in India and elsewhere. Sessions will focus on topics such as market size for TB diagnostics, IVD market analysis and value chain, target product profiles and market needs, frugal innovation and affordable diagnostics, intellectual property issues, regulation of diagnostics, sources of funding, prize models, business models for engaging private sector, scientific obstacles for R&D, barriers to innovation in India, academia-industry relations, and role of emerging economies and BRICS in the next wave of TB innovations. Confirmed speakers & panelists Anu Acharya, Ocimum Biosolutions, Hyderabad, India Tanjore Balganesh, AstraZeneca, Bangalore, India August 25 Steven Buchsbaum, Bill & Melinda Gates Foundation, USA Sanjeev Chaudhry, SRL, India Vir S. Chauhan, ICGEB, New Delhi, India Anand Daniel, Accel Partners, Bangalore, India Dhananjaya Dendukuri, Achira Labs, Bangalore, India TB diagnostics in India - Pradip Desai, Span Diagnostics, Surat, India 2011 26, Bindu Dey, Department of Biotechnology, New Delhi, India From importation and imitation to innovation Puneet Dewan, WHO, SEARO, New Delhi, India August 25 - 26, 2011, Bangalore, India Sami Guzder, Avesthagen, Bangalore, India Hosted by: St. John’s Research Institute,
    [Show full text]
  • Recent Developments in Genomics, Bioinformatics and Drug Discovery to Combat Emerging Drug-Resistant Tuberculosis
    Tuberculosis 101 (2016) 31e40 Contents lists available at ScienceDirect Tuberculosis journal homepage: http://intl.elsevierhealth.com/journals/tube REVIEW Recent developments in genomics, bioinformatics and drug discovery to combat emerging drug-resistant tuberculosis * Soumya Swaminathan a, , Jagadish Chandrabose Sundaramurthi b, Alangudi Natarajan Palaniappan c, Sujatha Narayanan d a National Institute for Research in Tuberculosis (ICMR), Chetpet, Chennai, 600031, India b Division of Biomedical Informatics, Department of Clinical Research, National Institute for Research in Tuberculosis (ICMR), Chetpet, Chennai, 600031, India c Department of Clinical Research, National Institute for Research in Tuberculosis (ICMR), Chetpet, Chennai, 600031, India d Department of Immunology, National Institute for Research in Tuberculosis (ICMR), Chetpet, Chennai, 600031, India article info summary Article history: Emergence of drug-resistant tuberculosis (DR-TB) is a big challenge in TB control. The delay in diagnosis Received 24 February 2016 of DR-TB leads to its increased transmission, and therefore prevalence. Recent developments in genomics Received in revised form have enabled whole genome sequencing (WGS) of Mycobacterium tuberculosis (M. tuberculosis) from 3- 21 May 2016 day-old liquid culture and directly from uncultured sputa, while new bioinformatics tools facilitate to Accepted 8 August 2016 determine DR mutations rapidly from the resulting sequences. The present drug discovery and devel- opment pipeline is filled with candidate drugs which have shown efficacy against DR-TB. Furthermore, Keywords: some of the FDA-approved drugs are being evaluated for repurposing, and this approach appears Drug-resistant tuberculosis fi Whole genome sequencing promising as several drugs are reported to enhance ef cacy of the standard TB drugs, reduce drug Bioinformatics tolerance, or modulate the host immune response to control the growth of intracellular M.
    [Show full text]
  • Health Technology Assessment Stakeholder's Consultative Workshop 25Thjuly, 2016, India Habitat Centre, New Delhi, India
    Health Technology Assessment Stakeholder’s Consultative Workshop 25thJuly, 2016, India Habitat Centre, New Delhi, India Introduction On the 25th July, 2016, a workshop was jointly convened by the Department of Health research (DHR), Government of India, The Indian Council of Medical Research (ICMR), and the international Decision Support initiative (IDSI) in order to raise awareness of the initiative to institutionalise health technology assessment (HTA) in India. This initiative aims to introduce a more transparent, inclusive, fair, and evidence-based process by which decisions regarding the allocation of health resources are made in India. The official government press release for the event highlighted the interest of the Indian government to utilise the event to learn from international iDSI partners on how HTA can be best utilised to improve access to affordable health care for the people of India towards the ultimate goal of Universal Health Coverage (UHC). The workshop provided the opportunity for key stakeholders within the field to share experiences, and engage in rich discussion and debate regarding the context, need, function, structure, and future plans for this initiative. The conference was well attended with over 200 delegates, including senior members of the Indian government such as the 2 newly appointed ministers of state for health, Shri Faggan Singh Kulaste and Smt Anupriya Patel; The DG of health services, Mr Jagdish Prasad; and the secretary of DHR, Dr Soumya Swaminathan. Speakers at the event included distinguished leaders of health research and public health strategy in India, including Mr Manoj Jhalani, Joint Secretary and Mission Director (NHM), Ministry of Health and Family Welfare, Prof S.
    [Show full text]
  • Looking Forward: Avoiding a Vaccine Cold War” a Recap Featuring World Renown Scientists and Doctors Discussing the Realities of the COVID-19 Pandemic
    All the Best Podcast Episode 48: “Looking Forward: Avoiding a Vaccine Cold War” A recap featuring world renown scientists and doctors discussing the realities of the COVID-19 pandemic Dr. Murphy: The 41st president, George H. W. Bush, was known for many things, but one of which was truly the leader of a team, the assemblage of a team, the inspiration of a team. He had three aspects that he shared with me. He said in crucial things, unity, in important things, diversity and in all things generosity. George: In the first place, I believe that character is a part of being President. Barbara: And life really must have joy. Sam: This is "All the Best." The official podcast of the George and Barbara Bush Foundation. I'm your host, Sam LeBlond, one of their many grandchildren. Here, we celebrate the legacy of these two incredible Americans through friends, family, and the foundation. This is "All the Best." George: I remember something my dad taught me. He said, write your mother, serve your country, and he said, tell the truth. And I've tried to do that in public life. All through it. Barbara: You are a human being first and those human connections with children, with friends are the most important investments you will ever make. George: We stand tonight before a new world of hope and possibilities for our children. A world we could not have contemplated a few years ago. Sam: On behalf of our family and the George and Barbara Bush Foundation. This is "All the Best." ATB Podcast – Vaccine Recap Oct 2020 2 Welcome to "All the Best." I'm your host, Sam LeBlond.
    [Show full text]
  • Kaivan Munshi
    Kaivan Munshi Department of Economics Yale University Hillhouse Avenue 203-432-4479 [email protected] Education Ph.D. Economics Massachusetts Institute of Technology 1995 M.S., M.C.P. University of California, Berkeley 1989 B.Tech. Indian Institute of Technology, Bombay 1986 Honors and Awards 2019 Distinguished Alumnus Award, IIT Bombay 2016 Infosys Prize for the Social Sciences Positions Held 2020 Faculty Research Associate, National Bureau of Economic Research (NBER) 2019 Professor, Department of Economics, Yale University 2018 Associate Member, Toulouse School of Economics 2015-2019 Research Fellow, Centre for Economic Policy Research (CEPR) 2015 Research Fellow, Institute for the Study of Labor (IZA) 2015-2019 Research Fellow, Institute for Fiscal Studies (IFS) 2015-2017 Professorial Fellow, Magdalene College 2014 Research Associate, Harvard-Cambridge Joint Centre for History and Economics 2013-2019 Frank Ramsey Professor of Economics, University of Cambridge 2013 Research Fellow, Centre for Research and Analysis of Migration (CReAM) 2013 Research Associate, Population Research Institute, Pennsylvania State University 2013-2015 Visiting Senior Scholar, Department of Economics, Pennsylvania State University 2011 Associate, Theoretical Research in Development Economics (ThReD) 2010-2016 Co-editor, Journal of Development Economics 2008-2012 Permanent Member, NIH Social Sciences and Population Studies (SSPS) Study Section 2007-2012 Associate Editor, American Economic Review 2007-2008 Associate Editor, Economic Development and Cultural
    [Show full text]
  • 2020 International Cohorts Summit Executive Summary
    MEETING SUMMARY Virtual Summit Zoom May 4-5, 2020 Hosted by the Global Genomic Medicine Collaborative (G2MC) ihccglobal.org Vision for success: TO CREATE A GLOBAL NETWORK FOR TRANSLATIONAL RESEARCH THAT UTILIZES LARGE COHORTS TO ENHANCE THE UNDERSTANDING OF THE BIOLOGICAL AND GENETIC BASIS OF DISEASE AND IMPROVE CLINICAL CARE AND POPULATION HEALTH IHCC Third International Cohorts Virtual Summit Executive Summary In 2015, the National Institutes of Health (NIH) launched an effort to identify all large-scale prospective cohort studies involving at least 100,000 participants to explore the potential of bringing them together to address scientific questions none could answer alone. This effort led to the commission of the Global Genomic Medicine Collaborative (G2MC) to bring together these cohorts through the International HundredK+ Cohort Consortium (IHCC). This group gathered for the First International Cohort Summit in the USA in 2018 followed by a Second Summit in Iceland in 2019. During planning of the Third Summit to take place in Santiago, Chile, the global outbreak of COVID-19 required a transition to virtual meeting format. Approximately 160 attendees from more than 23 countries attended the virtual Summit. The event in Santiago, Chile will be postponed to a date to be determined when attendee health and safety will not be at heightened risk due to COVID-19. The virtual meeting objectives included: To galvanize the IHCC around a visionary charter and path forward (defining the IHCC organization, mission, membership, partnership opportunities, industry engagement). To examine how IHCC can rapidly mobilize worldwide cohorts to address the COVID-19 pandemic. To introduce the IHCC to a Cohort Data Atlas that can be used to stimulate and enable collaborations among cohorts.
    [Show full text]
  • COVID-19 Vaccine Development, Strategy and Implementation
    Symposium: Vaccines and Global Health: COVID-19 Vaccine Development, Strategy and Implementation The Program in Vaccine Education at the Columbia University Vagelos College of Physicians & Surgeons’ mission is to educate medical students and to inform health care professionals, public health experts, academic, government and industry researchers, policy makers, global health non-governmental organizations, journalists, and the general public as to the cutting-edge advances and challenges in modern vaccine development. The Columbia University convenors are Drs. Lawrence Stanberry (Co-Director, PVE), Philip LaRussa (Co-Director, PVE), Wilmot James (Associate Director, PVE), and Marc Grodman (Special Advisor, PVE). We have put together a group of 25 outstanding speakers who have been intimately involved with all aspects of COVID-19 vaccine development, strategy, and implementation. We are delighted to present this five-day virtual symposium at the cusp of the world’s transition to controlling the COVID-19 pandemic. Monday, February 22 National, Regional and Global Response to an Unprecedented Challenge 12:00-12:10 Welcome: Lee Bollinger, JD – President, Columbia University 12:10-12:15 Moderator: Lawrence R. Stanberry, MD, PhD – Director of the Programs in Global Health, Columbia University Vagelos College of Physicians and Surgeons 12:15-12:45 Keynote: Sir Jeremy Farrar, BSc, MBBS, PhD – Director, Wellcome Trust The Role of the Wellcome Trust in COVID-19 Vaccine Preparedness 12:45-1:30 Speakers: - Shabir Madhi, MBChB, MMed, FCPaeds PhD – Professor of Vaccinology, University of the Witwatersrand – A South African perspective on vaccine preparedness and availability. - Nancy Messonnier, MD – Director, National Center for Immunization and Respiratory Diseases, US CDC – A US CDC perspective on vaccine preparedness and availability.
    [Show full text]
  • Who-Hq-Organigram.Pdf
    World Health Organization Headquarters* (as of 10 May 2021) Director-General (1) Dr Tedros Adhanom *Click on the Division for further details GHEBREYESUS WHO Office at the Chef de Cabinet (1) Dr Catharina BOEHME United Nations Mr Stewart SIMONSON Envoy for Multilateral Affairs Dr Agnès BUZYN Deputy Director-General (2) Health Emergencies Dr Zsuzsanna JAKAB Preparedness and Response Dr Michael RYAN External Relations and Business Operations Data, Analytics and Chief Scientist UHC/Life Course UHC/Communicable and UHC/Healthier Antimicrobial Resistance Access to Medicines and Emergency Response Emergency Preparedness 4 Governance Mr Raul THOMAS Delivery for Impact and Science Division Dr Zsuzsanna JAKAB (a.i.) Noncommunicable Populations Dr Hanan BALKHY Health Products Dr Soce FALL Dr Jaouad MAHJOUR Ms Jane ELLISON Dr Samira ASMA Dr Soumya SWAMINATHAN Diseases Dr Ren MINGHUI Dr Naoko YAMAMOTO Dr Mariangela SIMÃO Planning,Resource Quality Assurance of Special Programme on Global Malaria Environment, Climate Surveillance, Health Product Policy Health Emergency Health Security Governing Bodies Coordinationand Data and Analytics PerformanceMonitoring Norms and Standards Primary Health Care Programme Change and Health Prevention and Control and Standards Interventions Preparedness Digital Health and Control of Neglected Social Determinants Global Coordination Regulation and Health Emergency Resource Mobilization Finance Health Workforce Global Infectious Innovation Tropical Diseases of Health and Partnership Prequalification Informationand Risk
    [Show full text]
  • Virtual Press Conference 27 August 2020
    COVID-19 Virtual Press conference 27 August 2020 Speaker key: MH Margaret Harris TAG Tedros Adhanom Ghebreyesus ST Stephanie MK Dr Maria Van Kerkhove MR Dr Michael Ryan JO Josephine LA Laurent NI Nina BA Dr Bruce Aylward MA Mahab SS Dr Soumya Swaminathan AD Adam TH Theo LA Latika JI Jim BI Bianca 00:00:11 MH Hello, everybody. This is Margareta Harris in WHO headquarters, Geneva welcoming you to our global press conference on COVID-19 today, this Thursday August 27th. We have with us as always in the room the WHO Director-General, Dr Tedros, along with Dr Jaouad Mahjour, our Assistant Director- General for Emergency Preparedness and the International Health Regulations, Dr Maria Van Kerkhove, Technical Lead for COVID-19, Dr Bruce Aylward, Senior Advisor to the Director- General, who leads on the ACT Accelerator, and Devora Kestel, Director of our Mental Health and Substance Use department. Dr Mariangela Simao will join us later and we're also being joined remotely by Dr Mike Ryan, Executive Director of our Emergencies Programme, and Dr Soumya Swaminathan, our Chief Scientist. As usual we are translating this simultaneously into the six official UN languages plus Portuguese and Hindi and we'll be posting the Director-General's remarks and an audio file of the press conference on the web as soon as possible. Transcripts will also be available later. Now without further delay I will hand over to Dr Tedros to give his opening remarks. Dr Tedros, you have the floor. TAG Thank you. Thank you, Margareta. Good morning, good afternoon and good evening.
    [Show full text]